WuXi Biologics Wins Two Grand Awards at 2026 Hong Kong ESG Awards
HONG KONG – November 03, 2026 -- WuXi Biologics (2269.HK) won two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), the only pharmaceutical company to do so among 120 entries.
The contract research, development and manufacturing organization (CRDMO) took Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact. HERA categories span ESG governance, environmental and social impact, carbon neutrality and workplace well-being. A panel drawn from academia, finance, sustainability advisory and regulatory backgrounds judges the program independently.
SBTi validated WuXi Biologics' emissions targets across Scope 1, 2 and 3 in 2025
The Science Based Targets initiative (SBTi) validated the company's near-term, long-term and net-zero greenhouse gas reduction targets in 2025. The targets cover Scope 1, 2 and 3 emissions and align with a 1.5°C pathway.